| Pharmaceutical Information |
| Drug Name |
Albiglutide |
| Drug ID |
BADD_D00053 |
| Description |
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. |
| Indications and Usage |
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Marketing Status |
Prescription |
| ATC Code |
A10BJ04 |
| DrugBank ID |
DB09043
|
| KEGG ID |
D08843
|
| MeSH ID |
C534611
|
| PubChem ID |
145994868
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| Synonyms |
rGLP-1 protein | Eperzan | Tanzeum | albiglutide |
|
| Chemical Information |
| Molecular Formula |
C148H224N40O45 |
| CAS Registry Number |
782500-75-8 |
| SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)N
C(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)N
C(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)
C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(
=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(
CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
